Dosing Begins in Solengepras Parkinson’s Therapy Phase 3 Trial
Cerevance has initiated the Phase 3 ARISE trial to evaluate solengepras, a non-dopaminergic therapy targeting specific brain circuits, as a potential adjunctive treatment for Parkinson's disease.